Northcape Wealth Management’s Gilead Sciences GILD Stock Holding History

Northcape Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$232K	Buy	1,834 +3	+0.2%	+$395	0.06%	137
2026 Q1	$255K	Buy	1,831 +21	+1%	+$2.94K	0.07%	128
2025 Q4	$222K	Sell	1,810 -182	-9%	-$22.1K	0.06%	133
2025 Q3	$221K	Buy	1,992 +5	+0.3%	+$568	0.06%	132
2025 Q2	$220K	Sell	1,987 -65	-3%	-$6.92K	0.07%	134
2025 Q1	$230K	Buy	+2,052	New	+$212K	0.07%	128
2022 Q4	–	Sell	-5,984	Closed	-$369K	–	94
2022 Q3	$369K	Buy	+5,984	New	+$377K	0.13%	107
2022 Q2	–	Sell	-5,655	Closed	-$336K	–	127
2022 Q1	$336K	Buy	+5,655	New	+$361K	0.1%	121

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northcape Wealth Management's GILD Position: Q2 2026 in Review

Northcape Wealth Management increased its Gilead Sciences (GILD) stake by 0.16% in Q2 2026, buying an estimated $395 and bringing the position to 1,834 shares worth $232K. The position accounts for 0.06% of the portfolio, ranked #137.

Northcape Wealth Management first reported a position in GILD in Q1 2022 and has held it in 8 quarters since. The position peaked at $369K in Q3 2022. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Northcape Wealth Management held 1,834 shares of Gilead Sciences worth $232K as of Q2 2026.
Northcape Wealth Management bought 3 Gilead Sciences shares in Q2 2026, an estimated $395.
Gilead Sciences made up 0.06% of Northcape Wealth Management's portfolio in Q2 2026, its #137 holding.
Northcape Wealth Management first reported a position in Gilead Sciences in Q1 2022 and has held it in 8 quarters since.
Northcape Wealth Management's Gilead Sciences position peaked at $369K in Q3 2022.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Northcape Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.